[CLSTR]
< Back to situations

We’ll email you as it develops, and you can follow the whole thread from day one.

[SITUATION] · [ACTIVE]

2 clusters · 2 sources · 18 days · First seen · Last updated

Categories: BUSINESS

Goldman Sachs hedge fund activity

Entities: Goldman Sachs · Food and Drug Administration · U.S. healthcare stocks · Trium Capital · Felix Lo

Overview

In early July, Goldman Sachs noted a rebound in hedge‑fund strategies as AI‑driven trading activity weakened, signalling a broader recovery in the sector. By late July, the firm highlighted a shift in fund allocations, with hedge funds reaching a near five‑year high in exposure to U.S. healthcare equities. This surge was fueled by advances in AI‑driven drug discovery, heightened M&A activity, and an accelerated FDA approval pace. Specialized healthcare hedge funds posted markedly higher returns than generalist peers, and a growing share of new hedge‑fund launches now target the healthcare space. Overall, the reports trace a move from a general strategy rebound toward concentrated investment in AI‑enabled healthcare opportunities.

Timeline

  1. 1 day ago

    [BUSINESS] 2 sources
    Goldman Sachs reports hedge funds near five‑year high on U.S. healthcare stocks

    Hedge‑fund exposure to U.S. healthcare stocks hit a five‑year high, driven by AI‑enabled drug breakthroughs and strong M&A, with specialist funds posting ~40 % returns, Goldman Sachs reports.

  2. 19 days ago

    [BUSINESS] 2 sources
    Goldman Sachs reports hedge fund strategy rebound as AI‑driven trades wobble

    Goldman Sachs notes a rebound in active‑extension hedge fund assets to $153 bn, while AI‑focused quant funds see performance dip to 10.8 % after a market reversal.

Sources

paparazzi.com.ar · wtvbam.com